CRISPR Therapeutics Announces Transition of Bill Lundberg, MD
February 08 2018 - 4:30PM
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company
focused on developing transformative gene-based medicines for
serious diseases, today announced that Bill Lundberg, MD, is
stepping down as Chief Scientific Officer of CRISPR. Going forward,
Dr. Lundberg will serve as a Senior Advisor to the Company and has
been named Head of CRISPR’s Scientific Advisory Board.
“I have had the privilege of working with a wonderful, talented
and dedicated group of people at CRISPR Therapeutics,” said Dr.
Lundberg. “We have filed the first company-sponsored clinical
trial applications for CRISPR-based therapies, and now is a natural
time for me to transition to a Senior Advisor role. I am confident
in the success of the CRISPR team to continue to advance important
gene-based medicines for patients suffering from devastating
diseases.”
“Bill was instrumental in establishing our research operations
and advancing our CRISPR/Cas9 platform from the research phase to
clinical evaluation. On behalf of CRISPR Therapeutics, I thank Bill
for his leadership and look forward to his continued involvement,”
commented Samarth Kulkarni, PhD, CEO of CRISPR Therapeutics.
“CRISPR will continue to build on this foundation under the
leadership of Dr. Tony Ho, Head of R&D, to advance our mission
of translating the CRISPR/Cas9 platform into transformative
medicines.”
About CRISPR
Therapeutics
CRISPR Therapeutics is a leading
gene-editing company focused on developing transformative
gene-based medicines for serious diseases using its proprietary
CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary
technology that allows for precise, directed changes to genomic
DNA. The company's multi-disciplinary team of world-class
researchers and drug developers is working to translate this
technology into breakthrough human therapeutics in a number of
serious diseases. Additionally, CRISPR Therapeutics has
established strategic collaborations with Bayer
AG and Vertex Pharmaceuticals to develop
CRISPR-based therapeutics in diseases with high unmet need. The
foundational CRISPR/Cas9 patent estate for human therapeutic use
was licensed from the company's scientific founder Emmanuelle
Charpentier, Ph.D. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations
based in Cambridge, Massachusetts. For more information,
please visit http://www.crisprtx.com.
CRISPR Forward-Looking
Statement
Certain statements set forth in this press
release constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, as
amended, including, but not limited to, statements concerning: the
timing of filing of clinical trial applications and INDs and timing
of commencement of clinical trials, the intellectual property
coverage and positions of the Company, its licensors and third
parties, the sufficiency of the Company’s cash resources and the
therapeutic value, development, and commercial potential of
CRISPR/Cas9 gene editing technologies and therapies. You are
cautioned that forward-looking statements are inherently uncertain.
Although the Company believes that such statements are based on
reasonable assumptions within the bounds of its knowledge of its
business and operations, the forward-looking statements are neither
promises nor guarantees and they are necessarily subject to a high
degree of uncertainty and risk. Actual performance and results may
differ materially from those projected or suggested in the
forward-looking statements due to various risks and uncertainties.
These risks and uncertainties include, among others: uncertainties
regarding the intellectual property protection for our technology
and intellectual property belonging to third parties; uncertainties
inherent in the initiation and completion of preclinical studies
for the Company’s product candidates; availability and timing of
results from preclinical studies; whether results from a
preclinical trial will be predictive of future results of the
future trials; expectations for regulatory approvals to conduct
trials or to market products; and those risks and uncertainties
described under the heading “Risk Factors” in the Company’s most
recent annual report on Form 10-K, and in any other subsequent
filings made by the Company with the U.S. Securities and
Exchange Commission (SEC), which are available on the SEC’s
website at www.sec.gov. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date they are made.
CONTACTS
CRISPR Therapeutics
Investors:Chris Erdman 617-307-7227
chris.erdman@crisprtx.comorChris Brinzey Westwicke
Partners339-970-2843chris.brinzey@westwicke.com
Media:Jennifer Paganelli WCG for CRISPR 347-658-8290
jpaganelli@wcgworld.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Aug 2024 to Sep 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Sep 2023 to Sep 2024